Mitarbeitende

Dr. med. Silvan Vesenbeckh

Oberarzt

Portrait Dr. med. Silvan Vesenbeckh

Vesenbeckh S
Last Minute Infektiologie, Immunologie und Mikrobiologie.
(Urban & Fischer Verlag/Elsevier GmbH, Aug 2013)

Vesenbeckh S, Schönfeld N, Roth A, Bettermann G, Krieger D, Bauer TT, Rüssmann H, Mauch H. Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections. (Eur Respir J. 2017 May 21;49(5))

Vesenbeckh S, Schönfeld N, Krieger D, Bettermann G, Bauer TT, Rüssmann H, Mauch H. Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections. (Eur Respir J. 2017 Mar 22;49(3))

Otto-Knapp R, Vesenbeckh S, Schönfeld N, Bettermann G, Roth A, Bauer T, Rüssmann H, Mauch H. In reply. (Int J Tuberc Lung Dis. 2017 Jan 1;21(1):123)

Krieger D, Schönfeld N, Vesenbeckh S, Bettermann G, Bauer TT, Rüssmann H, Mauch H.Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare? (Eur Respir J. 2016 Dec;48(6):1803-1804)

Otto-Knapp R, Vesenbeckh S, Schönfeld N, Bettermann G, Roth A, Bauer T, Rüssmann H, Mauch H. Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation. (Int J Tuberc Lung Dis. 2016 Sep;20(9):1275-6)

Vesenbeckh S, Krieger D, Bettermann G, Schönfeld N, Bauer TT, Rüssmann H, Mauch H. Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different phenothiazines against Mycobacterium tuberculosis. (Tuberculosis (Edinb). 2016 May;98:27-9)

Hernán García C, Moreno Cea L, Fernández Espinilla V, Ruiz Lopez Del Prado G, Fernández Arribas S, Andrés García I, Rubio V, Vesenbeckh S, Eiros Bouza JM. Outbreak of isoniazid-resistant tuberculosis in an immigrant community in Spain. (Arch Bronconeumol. 2015 Nov 12, epub ahead of print)

Krieger D, Vesenbeckh S, Schönfeld N, Bettermann G, Bauer TT, Rüssmann H, Mauch H. Mefloquine as a potential drug against multidrug-resistant tuberculosis. (Eur Respir J. 2015 Nov;46(5):1503-5)

Vesenbeckh S, Wagner S, Mauch H, Roth A, Streubel A, Rüssmann H, Bauer TT, Matthiessen W, Schönfeld N. Pathogenität von Mycobacterium kansasii. (Pneumologie. 2014 Aug;68(8):526-31)

Otto-Knapp R, Bös L, Schönfeld N, Wagner S, Starzacher AK, Weiss T, Vesenbeckh S, Glaser-Paschke G, Mauch H, Rüssmann H, Bauer TT. Resistance to second-line drugs in migrants with multidrug-resistant tuberculosis in the Berlin region. (Pneumologie. 2014 Jul;68(7):496-500)

Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, et al. Global Mortality Estimates for the 2009 Influenza Pandemic from the GLaMOR Project: A Modeling Study. (PLoS Med. 2013 Nov;10(11):e1001558)

Bompangue D, Le Duc G, Vesenbeckh S, Blackwell N. Letter: Prospects for the elimination of cholera from the island of Hispaniola, hope for the fight against cholera in Africa. (Lancet. 2012 Mar 31;379(9822):e46-7)

Rinaldo A, Bertuzzo E, Mari L, Righetto L, Blokesch M, Gatto M, Casagrandi R, Murray M, Vesenbeckh SM, Rodriguez-Iturbe I. Reassessment of the 2010-2011 Haiti cholera outbreak and rainfall-driven multi-season projections. (Proc Natl Acad Sci USA. 2012 Apr 24;109(17):6602-7)

Bompangue D, Vesenbeckh SM, Giraudoux P, Marcia C, Muyumbe Tamfum JJ, Kabela Ilunga B, Murray M. Cholera ante portas – The re-emergence of Cholera in Kinshasa after a ten-years hiatus. (Bompangue/Vesenbeckh contributed equally. PLoS Currents Disasters, 2012 Feb 17 [revised 2012 Mar 12];4:RRN1310)

Schönfeld N, Bergmann T, Vesenbeckh SM, Mauch H, Bettermann G, Bauer TT, Rüssmann H. Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolates. (Lung India. 2012 Oct;29(4):309-12.)

Vesenbeckh SM, Schönfeld N, Mauch H,  Bergmann T, Wagner S, Bauer TT, Rüssmann H. The Use of Interferon Gamma Release Assays in the Diagnosis of Active Tuberculosis. (Tuberculosis Res Treat. 2012;2012:768723)

Vesenbeckh SM, Becker J, Huhnt C, Karras B, Bauer TT, Mauch H, Rüssmann H, Schönfeld N. Successful oral desensitization to i.v. paraaminosalicylic acid (PAS) using encapsulated PAS dry substance. (Infection. 2012 Apr;40(2):199-202.

Hofmann J, Meisel H, Klempa B, Vesenbeckh SM, Beck R, Michel D, Schmidt-Chanasit J, Ulrich RG, Grund S, Enders G, Kruger DH; Hantavirus Outbreak, Germany, 2007 (Emerg Infect Dis. 2008 May;14(5):850-2)

Morel GR, Reggiani PC, Console GM, Rimoldi OJ, Vesenbeckh SM, Garcia-Bravo MM, Rodriguez SS, Brown OA, Goya RG; Potential of Gene Therapy for Restoration of Endocrine Thymic Function in Thymus-Deficient Animal Models (Current Gene Therapy. 2008 Feb;8(1):49-53)

Goya RG, Reggiani PC, Vesenbeckh SM, Pléau JM, Sosa YE, Cónsole GM, Schade R, Henklein P, Dardenne M; Thymulin Gene Therapy prevents the Reduction in Circulating Gonadotropins induced by Thymulin Deficiency in Mice. (Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E182-7)

Camihort G, Luna G, Vesenbeckh SM, Ferese C, Dardenne M, Goya RG, Cónsole GM; Morphometric Assessment of the Impact of Serum Thymulin Immunoneutralization on Pituitary Cell Populations in Peripuberal Mice; (Cells Tissues Organs. 2006;184(1):23-30)

 

 

 

Kontakt Pneumologie / Thoraxchirurgie